ALRPRB.PFD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALRPRB.PFD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alere's yield on cost for the quarter that ended in Jun. 2017 was 2.99.
The historical rank and industry rank for Alere's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Alere's highest Yield on Cost was 4.66. The lowest was 0.00. And the median was 0.00.
For the Diagnostics & Research subindustry, Alere's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Alere's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Alere's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Alere is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Alere (NYSE:ALRPRB.PFD) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Alere's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
John Bridgen | officer: Sr VP, Business Development | 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453 |
Geoffrey S Ginsburg | director | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Renuka Uppaluri | officer: Senior VP, Global R&D | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Mark Gladwell | officer: Senior VP, Global Operations | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Gregg J Powers | director | C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110 |
Jonathan Wygant | officer: VP, Controller, CAO | 3750 TORREY VIEW COURT, SAN DIEGO X1 92130 |
Thomas Mckillop | director | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Melissa Guerdan | officer: SVP, Global Quality & Reg. | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Daniella Cramp | officer: Global Pres., Cardiometabolic | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Sanjay Malkani | officer: Global Pres., Toxicology | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
James Jr. Roosevelt | director | 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453 |
Robert Bernard Hargadon | officer: SVP, Global Human Resources | 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033 |
John F Levy | director | C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453 |
John Quelch | director | C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453 |
Carol R Goldberg | director | C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453 |
From GuruFocus
By Canadian Value Canadian Value • 01-23-2014
By Vera Yuan Vera Yuan • 10-17-2014
By Tiziano Frateschi Tiziano Frateschi • 02-26-2018
By Holly LaFon Holly LaFon • 11-21-2017
By Vera Yuan Vera Yuan • 03-17-2015
By Vatalyst.com Vatalyst.com • 02-28-2012
By Holly LaFon Holly LaFon • 09-17-2014
By Bavneet Singh Nagpal bavinagpal • 05-22-2015
By Carmine Romano Carmine Romano • 12-21-2011
By Alberto Abaterusso Alberto Abaterusso • 08-04-2017
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.